22nd Century Group, Inc. (XXII) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

100.79 k

Shareholding (Mar 2025)

FII

0.00%

Held by 12 FIIs

DII

99.73%

Held by 0 DIIs

Promoter

0.00%

How big is 22nd Century Group, Inc.?

22-Jun-2025

As of Jun 18, 22nd Century Group, Inc. has a market capitalization of 3.63 million, with net sales of 23.88 million and a net profit of -13.31 million over the last four quarters. Shareholder's funds are 4.01 million, and total assets are 21.67 million.

What does 22nd Century Group, Inc. do?

22-Jun-2025

22nd Century Group, Inc. is a plant biotechnology company that genetically modifies nicotine in tobacco and cannabinoids in cannabis. As of March 2025, it reported net sales of $6 million and a net loss of $3 million, with a market cap of $3.63 million.

Should I buy, sell or hold 22nd Century Group, Inc.?

22-Jun-2025

Who are in the management team of 22nd Century Group, Inc.?

22-Jun-2025

As of March 2022, the management team of 22nd Century Group, Inc. includes Ms. Nora Sullivan as Chairman of the Board, along with Independent Directors Dr. Michael Koganov, Mr. Roger O'Brien, and Mr. Richard Sanders.

Is 22nd Century Group, Inc. technically bullish or bearish?

20-Sep-2025

As of June 20, 2025, 22nd Century Group, Inc. shows a mildly bearish trend, with daily moving averages indicating bearish momentum, while weekly indicators present mixed signals, and the stock has underperformed the S&P 500 with a year-to-date return of -98.56%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor Management Efficiency with a low ROCE of 0%

The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward

Poor long term growth as Operating profit has grown by an annual rate 6.68% of over the last 5 years

Negative results in Jun 25

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 6 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

0.19

Return on Equity

-254.14%

Price to Book

1.09

Revenue and Profits:

Net Sales:

4 Million

(Quarterly Results - Jun 2025)

Net Profit:

-3 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-40.0%

6 Months

-93.91%

1 Year

-99.63%

2 Years

-99.99%

3 Years

-10.26%

4 Years

-100.0%

5 Years

-100.0%

22nd Century Group, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

22nd Century Group Hits New 52-Week Low at $1.56 Amidst Declining Sales

22nd Century Group, Inc. has reached a new 52-week low, reflecting ongoing financial difficulties. With a market capitalization of USD 6 million, the company reported a significant decline in net sales and a negative return on equity. Its stock performance has drastically underperformed compared to broader market indices.

Is 22nd Century Group, Inc. technically bullish or bearish?

As of 20 June 2025, the technical trend for 22nd Century Group, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearish momentum, while the weekly MACD and RSI show mildly bullish and bullish signals, respectively. However, the Bollinger Bands and KST are bearish, and Dow Theory indicates no trend on the weekly and bearish on the monthly. The stock has significantly underperformed against the S&P 500, with a year-to-date return of -98.56% compared to the S&P 500's 12.22%....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-5.97%

EBIT Growth (5y)

6.68%

EBIT to Interest (avg)

-24.87

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.85

Sales to Capital Employed (avg)

4.67

Tax Ratio

0.22%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.27%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.55

EV to EBIT

-0.73

EV to EBITDA

-0.81

EV to Capital Employed

1.30

EV to Sales

0.36

PEG Ratio

Dividend Yield

ROCE (Latest)

-177.84%

ROE (Latest)

-364.86%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 9 Schemes (0.27%)

Foreign Institutions

Held by 12 Foreign Institutions (0.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -31.67% vs 50.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 21.43% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.10",
          "val2": "6.00",
          "chgp": "-31.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.70",
          "val2": "-2.30",
          "chgp": "-17.39%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.60",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.30",
          "val2": "-3.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-730.10%",
          "val2": "-431.50%",
          "chgp": "-29.86%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -24.22% vs -20.49% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 71.66% vs -49.45% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "24.40",
          "val2": "32.20",
          "chgp": "-24.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.50",
          "val2": "-37.10",
          "chgp": "66.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.10",
          "val2": "9.40",
          "chgp": "-77.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-3.00",
          "chgp": "96.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-15.50",
          "val2": "-54.70",
          "chgp": "71.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-565.70%",
          "val2": "-1,304.30%",
          "chgp": "73.86%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

4.10

6.00

-31.67%

Operating Profit (PBDIT) excl Other Income

-2.70

-2.30

-17.39%

Interest

0.40

0.60

-33.33%

Exceptional Items

0.00

Consolidate Net Profit

-3.30

Operating Profit Margin (Excl OI)

-730.10%

-431.50%

-29.86%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -31.67% vs 50.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 21.43% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

24.40

32.20

-24.22%

Operating Profit (PBDIT) excl Other Income

-12.50

-37.10

66.31%

Interest

2.10

9.40

-77.66%

Exceptional Items

-0.10

-3.00

96.67%

Consolidate Net Profit

-15.50

-54.70

71.66%

Operating Profit Margin (Excl OI)

-565.70%

-1,304.30%

73.86%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -24.22% vs -20.49% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 71.66% vs -49.45% in Dec 2023

All Annual Results

Company CV

About 22nd Century Group, Inc.

22nd Century Group, Inc.

Pharmaceuticals & Biotechnology

22nd Century Group, Inc. is a plant biotechnology company. The Company is focused on technology that allows increasing or decreasing the level of nicotine and other nicotinic alkaloids in tobacco plants, and levels of cannabinoids in cannabis plants through genetic engineering and plant breeding. It is engaged in various activities, including research and development of less harmful or modified risk tobacco products and tobacco plant varieties; development of X-22, a smoking cessation aid consisting of very low nicotine (VLN) cigarettes; manufacture, marketing and distribution of its RED SUN and MAGIC cigarettes; production of SPECTRUM research cigarettes for the National Institute on Drug Abuse (NIDA); contract manufacturing of third-party branded tobacco products, and research and development of plant varieties of hemp/cannabis, such as plants with low to no amounts of delta-9-tetrahydrocannabinol (THC), plants with high levels of cannabidiol (CBD), and other non-THC cannabinoids.

Company Coordinates

Company Details

8560 Main St Ste 4 , WILLIAMSVILLE NY : 14221-7435

Tel: 1 716 2701523

http://www.xxiicentury.com/

Registrar Details

22nd Century Group, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is 22nd Century Group, Inc.?

Watch in Real-Time

What does 22nd Century Group, Inc. do?

Should I buy, sell or hold 22nd Century Group, Inc.?

Who are in the management team of 22nd Century Group, Inc.?

Is 22nd Century Group, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Poor Management Efficiency with a low ROCE of 0%

Poor long term growth as Operating profit has grown by an annual rate 6.68% of over the last 5 years

Negative results in Jun 25

Risky - Negative EBITDA

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

22nd Century Group Hits New 52-Week Low at $1.56 Amidst Declining Sales

Is 22nd Century Group, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About 22nd Century Group, Inc.

Company Coordinates